Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

Catheterization and Cardiovascular Interventions

Volumn 57, Issue 2, 2002, Pages 177-184

  Lewis, Bruce E ^a   Matthai Jr , William H ^b   Cohen, Marc ^c   Moses, Jeffrey W ^d   Hursting, Marcie J ^e   Leya, Fred ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^d LENOX HILL HEART AND VASCULAR INSTITUTE   (United States)

^e Clinical Science Consulting   (United States)

Author keywords

Anticoagulant; Direct thrombin inhibitor; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; HEPARIN; THROMBIN INHIBITOR; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTERY OCCLUSION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVASCULARIZATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VEIN GRAFT;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; ATHERECTOMY, CORONARY; FEMALE; HEPARIN; HUMANS; MALE; PIPECOLIC ACIDS; STENTS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

EID: 0036792725     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10276     Document Type: Article

References (21)

1. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
2. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629-635.
3. Brieger DB, Mak K-H, Kottke-Marchant C, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31:449-459.
4. Narins CR, Hillegass WB, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
5. Fareed J, Callas D, Hoppensteadt DA, Lewis BA, Bick RL, Walenga JM. Antithrombin agents as anticoagulants and anti-thrombotics: implications in drug development. Sem Hematol 1999;36(Suppl 1):42-56.
6. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
7. Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, van Dijk R, van den Dos AA, Umans VAWM, Fox KAA, Close P, Deckers JW, for the Helvetica Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763.
8. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG, for the ARG-911 Study Investigators. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
9. Lewis BE, Ferguson JJ, Grassman ED, Fareed J, Walenga J, Joffrion JL, Wrona L, Johnson SA, Schwarz RP, McKiernan T. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996;8:410-417.
10. Warkentin TE, Elavthil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-812.
11. Greinacher A, Warkentin TE. 2001. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Reinacher A, editors. Heparin-induced thrombocytopenia, 2nd ed. New York: Marcel Dekker. p 291-322.
12. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001;344:1286-1292.
13. Bittl JA, Chairman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-959.
14. Manfredi JA, Wall RP, Sane DC, Braden GA. Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports. Cathet Cardiovasc Intervent 2001;52:468-472.
15. Campbell KR, Mahaffey KW, Lewis BE, Weitz JI, Berkowitz SD, Ohman EM, Califf RM. Bivalirudin in patients with heparininduced thrombocytopenia undergoing percutaneous coronary intervention. J Invas Cardiol 2000;12(Suppl F):14F-19F.
16. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-1435.
17. The RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;1445-1453.
18. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
19. Laskey WK, Kimmel W, Krone RJ. Contemporary trends in coronary intervention: a report from the registry of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Intervent 2000;49:19-22.
20. Shubrooks SJ, Malenka DJ, Piper WD, Bradley WA, Watkins MW, Ryan TJ, Hettleman BD, VerLee PN, O'Meara JR, Robb JF, Kellett MA, Hearne MA, McGrath PD, Wennberg DE, O'Rourke DJ, Silver TM, for the Northern New England Cardiovascular Disease Study Group. Safety and efficacy of percutaneous coronary interventions performed immediately after diagnostic catheterization in northern New England and comparison with similar procedures performed later. Am J Cardiol 2000;86:41-45.
21. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost. 2001;86:427-443.